Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, ph...

Post time Half hour(s) ago

Lancet Oncol

. IF: 33.7Q1
2026 Sep;27(9):1077-1093.
doi: 10.1016/S1470-2045(26)00278-0.
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study Masatoshi Kudo 1, Ghassan K Abou-Alfa 2, Zhenggang Ren 3, Jeong Heo 4, Riccardo Lencioni 5, Yasuaki Arai 6, Mohamed Bouattour 7, Maria A Gonzalez-Carmona 8, Yabing Guo 9, Ai-Bing Xu 10, Gustavo Vasconcelos Alves 11, Arunee Dechaphunkul 12, Gwo Fuang Ho 13, Yueh Ni Lim 14, HongTao Hu 15, Ruibao Liu 16, Shanzhi Gu 17, Vikas Ostwal 18, Witsarut Manasirisuk 19, Chang-Fang Chiu 20, Sri Harsha Tekumalla 21, Manish Shroff 22, Vimal Dave 23, Osama Rahma 24, Joseph P Erinjeri 25, Jia Fan 26; EMERALD-3 Investigators

Collaborators, Affiliations Expand

[Elsevier] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, ph...